No abstract
specificity of MUC4 expression in our primary bone tumours, we included a series of soft tissue neoplasms, some of which rarely arise in bone. Tissue microarrays, prepared at our institution, included 120 high-grade osteosarcomas, 220 chondrosarcomas, 45 chordomas, 19 chondromyxoid fibromas, 22 chondroblastomas, 52 osteoblastomas, 60 myxofibrosarcomas, 54 solitary fibrous tumours, 59 leiomyosarcomas, 90 synovial sarcomas and 123 desmoid fibromatoses. Also included were whole tissue sections of eight ossifying fibromyxoid tumours, seven desmoplastic fibromas, 10 low-grade central osteosarcomas, 10 spindle cell sarcomas NOS of bone, 10 osteofibrous dysplasia/adamantinomas, five phosphaturic mesenchymal tumours and nine FUSrearrangement-negative SEF of soft tissue. Ten conventional FUS-rearrangement-positive LFS were included as positive controls. Standard immunohistochemistry was performed.All LFS were strongly and diffusely immunoreactive for MUC4. Four of nine (44.4%) SEF were diffusely positive for MUC4, whereas 22 of 90 (24.4%) synovial sarcomas showed focal immunoreactivity. All the remaining tumours tested were negative.Our findings demonstrate that primary bone tumours rarely express MUC4. We also confirm that MUC4 is rarely expressed diffusely in soft tissue spindle cell tumours, and that it is only seen focally in approximately 25% of synovial sarcoma. Hence, on the basis of the two diffusely immunoreactive MUC4 primary bone tumours which were identified, one with morphological features of LFS and the other of SEF, we consider that these represent rare examples of LFS and SEF arising in bone. We therefore recommend that MUC4 expression be studied in all fibromyxoid and sclerosing tumours of bone, in order to improve diagnostic accuracy when dealing with primary bone tumours. P et al. MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma. Am. J. Surg. Pathol. 2011; 35; 733-741. 2. Doyle LA, Wang WL, Dal Cin P et al. MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: association with FUS gene rearrangement. Am. J. Surg. Pathol. 2012; 36; 1444-1451. 3. Guillou L, Benhattar J, Gengler A et al. Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma. Am. J. Surg. Pathol. 2007; 31; 1387-1402. 4. Rekhi B, Folpe AL, Deshmukh M et al. Sclerosing epithelioid fibrosarcoma -a report of two cases with cytogenetic analysis of FUS gene rearrangement by FISH technique. Pathol. Oncol. Res. 2011; 17; 145-148. 5. Wang WL, Evans HL, Meis JM et al. FUS rearrangements are rare in 'pure' sclerosing epithelioid fibrosarcoma. Mod. Pathol. 2012; 25; 846-853. 6. Graham RPD, Dry S, Li X et al. Ossifying fibromyxoid tumor of soft parts: a clinicopathologic, proteomic and genomic study.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.